The significant EPS and revenue beat combined with raised guidance is a strong positive catalyst. Monitor the Q3 earnings call for sustainability of organic growth momentum and whether the tariff refund is a one-time benefit or signals broader trade policy tailwinds. The Novum IQ LVP shipment hold remains a headwind for Infusion Systems, but broad-based segment growth suggests underlying demand is solid.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $26.75entry
- T+1 · 4mo ago −2.21%α −2.91% · $26.16
- T+5 · 3mo ago +0.97%α −2.65% · $27.01
- T+20 · 3mo ago −3.07%α −7.03% · $25.93
- T+60 · 25d ago −5.42%α −7.89% · $25.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Baxter reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted EPS of $0.56 (vs $0.37 consensus, +51.4% beat) and revenue of $2.96B (vs $2.80B consensus, +5.7% beat). The company raised its full-year 2026 guidance: reported sales growth now 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), and adjusted EPS $1.95-$2.15 (from $1.85-$2.05). The beat was partly driven by a $0.11/share IEEPA tariff refund not previously contemplated in guidance.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS $0.56 vs consensus $0.37 (+51.4% beat)
- Q2 2026 revenue $2.96B vs consensus $2.80B (+5.7% beat)
- Revenue grew 5% YoY on both reported and organic basis, with all segments and divisions growing
- Full-year 2026 guidance raised: reported sales growth 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), adjusted EPS $1.95-$2.15 (from $1.85-$2.05)
- GAAP EPS $0.26 vs $0.24 YoY (+8%); adjusted EPS $0.56 vs $0.59 YoY (-5%) due to higher-cost inventory and cost reclassification, partially offset by $0.11/share tariff refund
- Free cash flow $181M in Q2, $257M YTD
- Quarterly dividend declared at $0.01/share, payable October 1, 2026
Financial Impact
EPS beat of $0.19 (51.4%) on $0.37 consensus; revenue beat of $160M (5.7%) on $2.80B consensus; guidance raised by $0.10-$0.10 at midpoint for adjusted EPS and 2-3pp for sales growth
Risk Factors
- The $0.11/share tariff refund is non-recurring and may not repeat in H2 2026
- Novum IQ LVP shipment and installation hold continues to pressure Infusion Systems sales
- Adjusted EPS still declined 5% YoY due to higher-cost inventory and cost reclassification headwinds
- Dividend remains at $0.01/share, signaling continued balance sheet constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-050795 |
| Document: bax-20260729.htm | 0001628280-26-050795 |
| Document: 0001628280-26-050795-index-headers.html | 0001628280-26-050795 |
| Document: 0001628280-26-050795-index.html | 0001628280-26-050795 |
| Document: 0001628280-26-050795.txt | 0001628280-26-050795 |
| 8-K Data (Synthetic) | 0001628280-26-050795 |
Track record
15 reports on BAX
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +9.15% at T+5 after the Oct 29, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $23.50 to $25.65 Now $25.54 +8.68% ▲ +9.15% +13.87% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $24.92 to $25.49 Now $25.54 +2.49% ▲ +2.29% +4.28% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $25.30 to $23.00 Now $25.54 +0.95% ▼ −9.09% −8.53% vs SPY
- Aug 19, 202612w ago 8-K Neutral 3/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
- Aug 18, 202612w ago 8-K Mixed 5/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 4/10 Entry $26.95 to $26.64 Now $25.54 −5.23% ▼ −1.15% −0.71% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $28.35 to $27.61 Now $25.54 −9.91% ▼ −2.61% −2.51% vs SPY
- Jul 30, 202615w ago 8-K Bullish 7/10 Viewing Entry $26.75 to $27.01 Now $25.54 −4.52% ▲ +0.97% −2.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $20.49 to $19.39 Now $25.54 −24.65% ▲ +5.37% +5.80% vs SPY
- May 8, 202627w ago 8-K Neutral 2/10 Entry $17.53 to $17.79 Now $25.54 +45.69% ▲ +1.48% +1.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers